**Figure S8 Legend:** ROC curves illustrate the inability of either ICOS IHC (A: n=40, AUC=0.5076) or PD-L1 IHC (B: n=39, AUC=0.5321) from archival (A,B) and pre-treatment (C,D) tumor tissue to predict emergence of an ICOS-hi CD4+ T cell population (C: n=30, AUC=0.6086; D: n=30, AUC=0.6131).

AUC, area under the curve; ICOS, inducible co-stimulator; ICOS-hi, patients with a CD4+ T-cell population expressing high levels of ICOS; IHC, immunohistochemistry; PD-L1, programmed death-ligand 1; ROC, receiver operator characteristic; TPS: tumor proportion scores.

Figure S8. **PD-L1 and ICOS IHC evaluated on archival and pre-treatment (fresh) tumor samples do not predict emergence of the pharmacodynamic biomarker ICOS-hi CD4 T cells**

